Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Historical Holders from Q1 2014 to Q2 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
RVNC
Shares outstanding
104,661,494
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Teoxane SA 6.2% 0% $32,335,404 6,550,800 0% Teoxane SA 30 Jan 2025
FRANKLIN RESOURCES INC 4.6% $23,617,550 4,784,658 Franklin Resources, Inc. 30 Sep 2024
Palo Alto Investors LP 1.5% $7,955,942 1,611,787 Patrick Lee, MD 30 Sep 2024

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q2 0 $0 -$425,554 0
2025 Q1 86,100 $425,000 -$245,915,234 $4.94 1
2024 Q4 81,615,726 $248,111,500 -$34,278,677 $3.04 169
2024 Q3 82,514,296 $428,141,597 +$73,554,744 $5.19 203
2024 Q2 81,380,096 $209,199,026 -$16,428,979 $2.57 172
2024 Q1 83,044,426 $408,576,667 +$33,183,947 $4.92 182
2023 Q4 34,201 $300,627 -$201,855 $8.79 1
2023 Q3 77,685,888 $891,079,390 -$145,567,704 $11.47 181
2023 Q2 81,597,941 $2,065,272,770 +$115,072,091 $25.31 210
2023 Q1 76,516,583 $2,464,233,486 +$117,644,613 $32.21 215
2022 Q4 73,748,021 $1,361,391,547 +$100,535,684 $18.46 186
2022 Q3 67,536,506 $1,821,529,107 +$324,818,754 $27.00 175
2022 Q2 55,780,275 $770,923,957 +$8,673,737 $13.82 152
2022 Q1 54,399,919 $1,060,603,136 +$29,983,679 $19.50 146
2021 Q4 52,490,585 $856,706,987 -$86,379,330 $16.32 139
2021 Q3 54,826,840 $1,527,481,962 +$20,185,748 $27.86 153
2021 Q2 53,794,598 $1,592,231,549 -$21,386,577 $29.64 156
2021 Q1 54,581,540 $1,525,520,506 +$56,425,874 $27.95 145
2020 Q4 52,592,482 $1,490,407,290 +$95,537,202 $28.34 145
2020 Q3 49,347,382 $1,242,933,966 -$27,121,551 $25.14 146
2020 Q2 49,867,878 $1,216,503,031 +$35,616,766 $24.42 135
2020 Q1 49,293,392 $729,753,856 -$25,443,570 $14.80 120
2019 Q4 50,824,274 $824,868,235 +$129,782,986 $16.23 125
2019 Q3 42,605,836 $553,941,602 -$12,407,642 $13.00 104
2019 Q2 43,043,659 $557,396,588 +$27,061,482 $12.97 108
2019 Q1 40,565,324 $639,315,834 +$98,451,099 $15.76 104
2018 Q4 31,723,980 $638,582,573 +$17,643,380 $20.13 95
2018 Q3 34,009,383 $845,132,934 -$21,938,902 $24.85 107
2018 Q2 31,084,230 $853,299,930 +$18,852,772 $27.45 107
2018 Q1 34,209,499 $1,053,625,660 -$32,732,651 $30.80 118
2017 Q4 34,942,553 $1,246,690,005 +$167,196,133 $35.75 113
2017 Q3 27,414,652 $754,198,335 -$1,518,505 $27.55 82
2017 Q2 27,519,844 $726,508,386 +$33,692,658 $26.40 84
2017 Q1 26,244,438 $545,878,202 +$45,353,932 $20.80 75
2016 Q4 26,079,545 $539,838,722 +$12,164,864 $20.70 79
2016 Q3 28,646,674 $464,359,406 -$1,079,896 $16.21 74
2016 Q2 28,754,017 $391,052,386 +$16,928,575 $13.60 76
2016 Q1 27,202,594 $474,934,380 -$25,985,490 $17.46 82
2015 Q4 27,209,685 $929,575,673 +$189,567,502 $34.16 101
2015 Q3 21,644,614 $644,108,702 +$32,787,105 $29.76 76
2015 Q2 20,375,790 $651,623,876 +$15,879,760 $31.98 86
2015 Q1 20,572,529 $426,440,171 +$18,581,352 $20.73 69
2014 Q4 19,756,513 $334,667,612 +$8,319,858 $16.94 67
2014 Q3 15,656,921 $302,653,761 -$45,141,249 $19.33 80
2014 Q2 16,359,430 $556,110,916 +$155,037,820 $34.00 97
2014 Q1 11,832,924 $372,736,175 +$371,917,123 $31.50 65